US 12,070,503 B2
Transdermal carrier
Bruce J. Sand, Westlake Village, CA (US); Ryan R. Beal, Camarillo, CA (US); and Philippe H. Burnham, Camarillo, CA (US)
Assigned to Dyve Biosciences, Inc., Camarillo, CA (US)
Filed by Dyve Biosciences, Inc., Camarillo, CA (US)
Filed on Sep. 21, 2022, as Appl. No. 17/934,056.
Application 17/934,056 is a continuation of application No. 17/361,158, filed on Jun. 28, 2021, granted, now 11,491,225.
Application 17/361,158 is a continuation of application No. 17/030,325, filed on Sep. 23, 2020, granted, now 11,052,152, issued on Jul. 6, 2021.
Application 17/030,325 is a continuation of application No. 16/119,178, filed on Aug. 31, 2018, granted, now 10,814,003, issued on Oct. 7, 2020.
Application 16/119,178 is a continuation of application No. 15/994,927, filed on May 31, 2018, abandoned.
Application 15/994,927 is a continuation of application No. 14/757,703, filed on Dec. 23, 2015, abandoned.
Application 14/757,703 is a continuation in part of application No. PCT/US2014/072239, filed on Dec. 23, 2014.
Claims priority of provisional application 62/261,167, filed on Nov. 30, 2015.
Claims priority of provisional application 62/238,012, filed on Oct. 6, 2015.
Claims priority of provisional application 62/198,605, filed on Jul. 29, 2015.
Claims priority of provisional application 62/198,599, filed on Jul. 29, 2015.
Claims priority of provisional application 62/191,952, filed on Jul. 13, 2015.
Claims priority of provisional application 62/187,756, filed on Jul. 1, 2015.
Claims priority of provisional application 62/178,232, filed on Apr. 6, 2015.
Claims priority of provisional application 62/178,192, filed on Apr. 2, 2015.
Claims priority of provisional application 62/178,193, filed on Apr. 2, 2015.
Claims priority of provisional application 62/177,814, filed on Mar. 24, 2015.
Claims priority of provisional application 62/176,419, filed on Feb. 17, 2015.
Claims priority of provisional application 62/176,415, filed on Feb. 17, 2015.
Claims priority of provisional application 62/176,414, filed on Feb. 17, 2015.
Claims priority of provisional application 62/176,417, filed on Feb. 17, 2015.
Claims priority of provisional application 62/176,438, filed on Feb. 17, 2015.
Claims priority of provisional application 62/176,418, filed on Feb. 17, 2015.
Claims priority of provisional application 62/176,416, filed on Feb. 17, 2015.
Prior Publication US 2023/0126804 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/24 (2006.01); A61F 13/00 (2006.01); A61F 13/02 (2006.01); A61K 8/02 (2006.01); A61K 8/04 (2006.01); A61K 8/34 (2006.01); A61K 8/36 (2006.01); A61K 8/37 (2006.01); A61K 8/42 (2006.01); A61K 8/49 (2006.01); A61K 8/55 (2006.01); A61K 8/86 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 31/196 (2006.01); A61K 31/245 (2006.01); A61K 31/454 (2006.01); A61K 31/7004 (2006.01); A61K 33/00 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/28 (2006.01); A61Q 7/00 (2006.01); A61Q 19/08 (2006.01)
CPC A61K 47/24 (2013.01) [A61F 13/00063 (2013.01); A61F 13/02 (2013.01); A61K 8/0291 (2013.01); A61K 8/042 (2013.01); A61K 8/34 (2013.01); A61K 8/36 (2013.01); A61K 8/37 (2013.01); A61K 8/42 (2013.01); A61K 8/4953 (2013.01); A61K 8/553 (2013.01); A61K 8/86 (2013.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/1075 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/196 (2013.01); A61K 31/245 (2013.01); A61K 31/454 (2013.01); A61K 31/7004 (2013.01); A61K 33/00 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/28 (2013.01); A61Q 7/00 (2013.01); A61Q 19/08 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method for impeding lactic acidosis in an individual, the method comprising administering to the individual a topical formulation for transdermal delivery of an active agent through the skin of a subject,
wherein the active agent comprises sodium bicarbonate,
wherein the topical formulation comprises: a lecithin at about 5%-15% w/w of the formulation, sodium bicarbonate at about 20%-40% w/w of the formulation, a poloxamer at about 1%-15% w/w of the formulation or an aqueous solution comprising about 15% -50% w/w poloxamer, an isopropyl palmitate, and menthol.